SUPERNUS PHARMACEUTICALS, INC. SUPN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
5.11
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $719.0M | -$38.5M | — | $46.0M | $1.1B |
| 2024 | $661.8M | $73.9M | — | $171.2M | $1.0B |
| 2023 | $607.5M | $1.3M | — | $110.5M | $921.5M |
| 2022 | $667.2M | $60.7M | — | $116.4M | $886.2M |
| 2021 | $579.8M | $53.4M | — | — | $815.9M |
| 2020 | $520.4M | $127.0M | — | $134.9M | $744.9M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.11 (safe)
- Working capital / assets 0.211
- Retained earnings / assets 0.357
- EBIT / assets -0.043
- Equity / liabilities 2.716
Source: SEC EDGAR filings · CIK 0001356576 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.